...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Asian journal of andrology >Chronic bacterial prostatitis and irritable bowel syndrome: effectiveness of treatment with rifaximin followed by the probiotic VSL#3
【24h】

Chronic bacterial prostatitis and irritable bowel syndrome: effectiveness of treatment with rifaximin followed by the probiotic VSL#3

机译：慢性细菌性前列腺炎和肠易激综合症：利福昔明联合益生菌VSL＃3的治疗效果

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

This study was undertaken to evaluate the influence of treatment with rifaximin followed by the probiotic VSL#3 versus no treatment on the progression of chronic prostatitis toward chronic microbial prostate-vesiculitis (PV) or prostate-vesiculo-epididymitis (PVE). A total of 106 selected infertile male patients with bacteriologically cured chronic bacterial prostatitis (CBP) and irritable bowel syndrome (IBS) were randomly prescribed rifaximin (200 mg, 2 tablets bid, for 7 days monthly for 12 months) and probiotic containing multiple strains VSL#3 (450 × 10 [9] CFU per day) or no treatment. Ninety-five of them (89.6%) complied with the therapeutic plan and were included in this study. Group A = "6Tx/6-": treatment for the initial 6 and no treatment for the following 6 months (n = 26); Group B = "12Tx": 12 months of treatment (n = 22); Group C = "6-/6Tx": no treatment for the initial 6 months and treatment in the last 6 months (n = 23); Group D = "12-": no treatment (n = 24). The patients of Groups A = "6Tx/6-" and B = "12Tx" had the highest frequency of chronic prostatitis (88.5% and 86.4%, respectively). In contrast, group "12-": patients had the lowest frequency of prostatitis (33.4%). The progression of prostatitis into PV in groups "6Tx/6-" (15.5%) and "6-/6Tx" (13.6%) was lower than that found in the patients of group "12-" (45.8%). Finally, no patient of groups "6Tx/6-" and "6-/6Tx" had PVE, whereas it was diagnosed in 20.8% of group "12-" patients. Long-term treatment with rifaximin and the probiotic VSL#3 is effective in lowering the progression of prostatitis into more complicated forms of male accessory gland infections in infertile patients with bacteriologically cured CBP plus IBS.
机译：进行这项研究以评估先用利福昔明再用益生菌VSL＃3进行治疗（相对于未治疗）对慢性前列腺炎向慢性微生物前列腺水疱病（PV）或前列腺水疱性上皮炎（PVE）的发展的影响。随机选择了106例经细菌学治愈的慢性细菌性前列腺炎（CBP）和肠易激综合征（IBS）的不育男性患者随机处方利福昔明（200 mg，2片bid，每月7天，共12个月）和含有多种VSL菌株的益生菌＃3（每天450×10 [9] CFU）或不进行治疗。他们中的百分之九十五（89.6％）符合治疗计划，被纳入本研究。 A组=“ 6Tx / 6-”：最初的6个治疗，随后的6个月不治疗（n = 26）; B组=“ 12Tx”：治疗12个月（n = 22）; C组=“ 6- / 6Tx”：最初6个月不进行治疗，而最近6个月不进行治疗（n = 23）; D组=“ 12-”：未治疗（n = 24）。 A =“ 6Tx / 6-”组和B =“ 12Tx”组的患者发生慢性前列腺炎的频率最高（分别为88.5％和86.4％）。相反，“ 12-”组：患者的前列腺炎发生率最低（33.4％）。 “ 6Tx / 6-”组（15.5％）和“ 6- / 6Tx”组（13.6％）的前列腺炎进展为PV，低于“ 12-”组（45.8％）的患者。最后，“ 6Tx / 6-”和“ 6- / 6Tx”组中没有患者患有PVE，而在“ 12-”组中有20.8％的患者被诊断为PVE。利福昔明和益生菌VSL＃3的长期治疗可有效降低细菌性CBP加IBS的不育患者前列腺炎向更复杂形式的男性副腺感染的进展。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号